

Joshua A Salomon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9062296/publications.pdf>

Version: 2024-02-01

291
papers

146,149
citations

3151

92
h-index

382

280
g-index

317
all docs

317
docs citations

317
times ranked

169283
citing authors

#	ARTICLE	IF	CITATIONS
1	Estimation of the Lifetime Quality-Adjusted Life Years (QALYs) Lost Due to Syphilis Acquired in the United States in 2018. <i>Clinical Infectious Diseases</i> , 2023, 76, e810-e819.	2.9	8
2	Population Immunity to Pre-Omicron and Omicron Severe Acute Respiratory Syndrome Coronavirus 2 Variants in US States and Counties Through 1 December 2021. <i>Clinical Infectious Diseases</i> , 2023, 76, e350-e359.	2.9	9
3	Cost-Effectiveness of 1-Time Universal Screening for Chronic Hepatitis B Infection in Adults in the United States. <i>Clinical Infectious Diseases</i> , 2022, 74, 210-217.	2.9	36
4	Trends, Mechanisms, and Racial/Ethnic Differences of Tuberculosis Incidence in the US-Born Population Aged 50 Years or Older in the United States. <i>Clinical Infectious Diseases</i> , 2022, 74, 1594-1603.	2.9	9
5	The Health and Economic Benefits of Tests That Predict Future Progression to Tuberculosis Disease. <i>Epidemiology</i> , 2022, 33, 75-83.	1.2	2
6	Adventures in COVID-19 Policy Modeling: Education Edition. <i>Current HIV/AIDS Reports</i> , 2022, 19, 94-100.	1.1	4
7	Problems with evidence assessment in COVID-19 health policy impact evaluation: a systematic review of study design and evidence strength. <i>BMJ Open</i> , 2022, 12, e053820.	0.8	12
8	Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Among Incarcerated People in California State Prisons: Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2022, 75, e838-e845.	2.9	16
9	Cost-Effectiveness of Dapagliflozin for Non-diabetic Chronic Kidney Disease. <i>Journal of General Internal Medicine</i> , 2022, 37, 3380-3387.	1.3	15
10	Evaluating spatially adaptive guidelines for the treatment of gonorrhea to reduce the incidence of gonococcal infection and increase the effective lifespan of antibiotics. <i>PLoS Computational Biology</i> , 2022, 18, e1009842.	1.5	1
11	Model-Estimated Association Between Simulated US Elementary School-Related SARS-CoV-2 Transmission, Mitigation Interventions, and Vaccine Coverage Across Local Incidence Levels. <i>JAMA Network Open</i> , 2022, 5, e2147827.	2.8	12
12	Affordability and Value in Decision Rules for Cost-Effectiveness: A Survey of Health Economists. <i>Value in Health</i> , 2022, , .	0.1	5
13	All-cause versus cause-specific excess deaths for estimating influenza-associated mortality in Denmark, Spain, and the United States. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 707-716.	1.5	11
14	Uptake of COVID-19 Vaccination Among Frontline Workers in California State Prisons. <i>JAMA Health Forum</i> , 2022, 3, e220099.	1.0	13
15	Estimated Transmission Outcomes and Costs of SARS-CoV-2 Diagnostic Testing, Screening, and Surveillance Strategies Among a Simulated Population of Primary School Students. <i>JAMA Pediatrics</i> , 2022, 176, 679.	3.3	11
16	Metamodeling for Policy Simulations with Multivariate Outcomes. <i>Medical Decision Making</i> , 2022, 42, 872-884.	1.2	4
17	The Household Secondary Attack Rate of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Rapid Review. <i>Clinical Infectious Diseases</i> , 2021, 73, S138-S145.	2.9	82
18	A review of network simulation models of hepatitis C virus and HIV among people who inject drugs. <i>International Journal of Drug Policy</i> , 2021, 88, 102580.	1.6	12

#	ARTICLE	IF	CITATIONS
19	Adaptive Policies to Balance Health Benefits and Economic Costs of Physical Distancing Interventions during the COVID-19 Pandemic. <i>Medical Decision Making</i> , 2021, 41, 386-392.	1.2	7
20	The Use and Misuse of Mathematical Modeling for Infectious Disease Policymaking: Lessons for the COVID-19 Pandemic. <i>Medical Decision Making</i> , 2021, 41, 379-385.	1.2	79
21	Mapping Inequality in SARS-CoV-2 Household Exposure and Transmission Risk in the USA. <i>Journal of General Internal Medicine</i> , 2021, 36, 1476-1478.	1.3	3
22	Better Late Than Never: Trends in COVID-19 Infection Rates, Risk Perceptions, and Behavioral Responses in the USA. <i>Journal of General Internal Medicine</i> , 2021, 36, 1825-1828.	1.3	12
23	Patterns of heavy drinking behaviour over age and birth cohorts among Chinese men: a Markov model. <i>BMJ Open</i> , 2021, 11, e043261.	0.8	2
24	Alternative Dose Allocation Strategies to Increase Benefits From Constrained COVID-19 Vaccine Supply. <i>Annals of Internal Medicine</i> , 2021, 174, 570-572.	2.0	71
25	How do Japanese rate the severity of different diseases and injuries? an assessment of disability weights for 231 health states by 37,318 Japanese respondents. <i>Population Health Metrics</i> , 2021, 19, 21.	1.3	13
26	Covid-19 Vaccine Acceptance in California State Prisons. <i>New England Journal of Medicine</i> , 2021, 385, 374-376.	13.9	37
27	Developing and evaluating a frailty index for older South Africans findings from the HAALSI study. <i>Age and Ageing</i> , 2021, 50, 2167-2173.	0.7	8
28	Racial/Ethnic Disparities In COVID-19 Exposure Risk, Testing, And Cases At The Subcounty Level In California. <i>Health Affairs</i> , 2021, 40, 870-878.	2.5	102
29	Impact of treatment duration on mortality among Veterans with opioid use disorder in the United States Veterans Health Administration. <i>Addiction</i> , 2021, 116, 3494-3503.	1.7	8
30	Concordance between fasting plasma glucose and HbA _{1c} in the diagnosis of diabetes in black South African adults: a cross-sectional study. <i>BMJ Open</i> , 2021, 11, e046060.	0.8	8
31	Impact Evaluation of Coronavirus Disease 2019 Policy: A Guide to Common Design Issues. <i>American Journal of Epidemiology</i> , 2021, 190, 2474-2486.	1.6	33
32	Modeling the Cost-Effectiveness of Express Multisite Gonorrhoea Screening Among Men Who Have Sex With Men in the United States. <i>Sexually Transmitted Diseases</i> , 2021, 48, 805-812.	0.8	4
33	COVID-19 in the California State Prison System: an Observational Study of Decarceration, Ongoing Risks, and Risk Factors. <i>Journal of General Internal Medicine</i> , 2021, 36, 3096-3102.	1.3	37
34	Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 926.	3.0	65
35	Passing the Test: A Model-Based Analysis of Safe School-Reopening Strategies. <i>Annals of Internal Medicine</i> , 2021, 174, 1090-1100.	2.0	26
36	Multimorbidity and mortality in an older, rural black South African population cohort with high prevalence of HIV findings from the HAALSI Study. <i>BMJ Open</i> , 2021, 11, e047777.	0.8	13

#	ARTICLE	IF	CITATIONS
37	Refining global HIV estimates for decision-making: advances in analytic and modelling methods used by the Joint United Nations Programme on HIV/AIDS. <i>Journal of the International AIDS Society</i> , 2021, 24, e25790.	1.2	3
38	Health Disparities And COVID-19: The Authors Reply. <i>Health Affairs</i> , 2021, 40, 1514-1514.	2.5	0
39	Outbreaks of COVID-19 variants in US prisons: a mathematical modelling analysis of vaccination and reopening policies. <i>Lancet Public Health</i> , The, 2021, 6, e760-e770.	4.7	35
40	Nationwide cost-effectiveness analysis of surgical stabilization of rib fractures by flail chest status and age groups. <i>Journal of Trauma and Acute Care Surgery</i> , 2021, 90, 451-458.	1.1	16
41	Time Since Infection and Risks of Future Disease for Individuals with Mycobacterium tuberculosis Infection in the United States. <i>Epidemiology</i> , 2021, 32, 70-78.	1.2	16
42	Dependence of COVID-19 Policies on End-of-Year Holiday Contacts in Mexico City Metropolitan Area: A Modeling Study. <i>MDM Policy and Practice</i> , 2021, 6, 238146832110492.	0.5	2
43	Balancing health and financial protection in health benefit package design. <i>Health Economics (United Kingdom)</i> 10.1016/j.healthecon.2021.08.002	0.8	2
44	Effectiveness of the mRNA-1273 Vaccine during a SARS-CoV-2 Delta Outbreak in a Prison. <i>New England Journal of Medicine</i> , 2021, 385, 2300-2301.	13.9	31
45	Quantifying and Benchmarking Disparities in COVID-19 Vaccination Rates by Race and Ethnicity. <i>JAMA Network Open</i> , 2021, 4, e2130343.	2.8	39
46	Lifetime burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis sequelae. <i>The Lancet Global Health</i> , 2021, 9, e1679-e1687.	2.9	74
47	The US COVID-19 Trends and Impact Survey: Continuous real-time measurement of COVID-19 symptoms, risks, protective behaviors, testing, and vaccination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	92
48	Cost-effectiveness and Budgetary Impact of Hepatitis C Virus Testing, Treatment, and Linkage to Care in US Prisons. <i>Clinical Infectious Diseases</i> , 2020, 70, 1388-1396.	2.9	23
49	Comparative Modeling of Tuberculosis Epidemiology and Policy Outcomes in California. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 356-365.	2.5	13
50	HIV treatment cascade for older adults in rural South Africa. <i>Sexually Transmitted Infections</i> , 2020, 96, 271-276.	0.8	12
51	Potential for Point-of-Care Tests to Reduce Chlamydia-associated Burden in the United States: A Mathematical Modeling Analysis. <i>Clinical Infectious Diseases</i> , 2020, 70, 1816-1823.	2.9	22
52	The Potential Population-Level Impact of Different Gonorrhea Screening Strategies in Baltimore and San Francisco: An Exploratory Mathematical Modeling Analysis. <i>Sexually Transmitted Diseases</i> , 2020, 47, 143-150.	0.8	5
53	The effects of changes in distance to nearest health facility on under-5 mortality and health care utilization in rural Malawi, 1980-1998. <i>BMC Health Services Research</i> , 2020, 20, 899.	0.9	17
54	Population-level Benefits of Extragenital Gonorrhea Screening Among Men Who Have Sex With Men: An Exploratory Modeling Analysis. <i>Sexually Transmitted Diseases</i> , 2020, 47, 484-490.	0.8	11

#	ARTICLE	IF	CITATIONS
55	Hepatitis C Management at Federally Qualified Health Centers during the Opioid Epidemic: A Cost-Effectiveness Study. <i>American Journal of Medicine</i> , 2020, 133, e641-e658.	0.6	5
56	Estimation and correction of bias in network simulations based on respondent-driven sampling data. <i>Scientific Reports</i> , 2020, 10, 6348.	1.6	1
57	High-resolution estimates of tuberculosis incidence among non-U.S.-born persons residing in the United States, 2000–2016. <i>Epidemics</i> , 2020, 33, 100419.	1.5	6
58	Mathematical modeling study of school-based chlamydia screening: potential impact on chlamydia prevalence in intervention schools and surrounding communities. <i>BMC Public Health</i> , 2020, 20, 1363.	1.2	2
59	Policy Implications of Mathematical Modeling of Latent Tuberculosis Infection Testing and Treatment Strategies to Accelerate Tuberculosis Elimination. <i>Public Health Reports</i> , 2020, 135, 38S-43S.	1.3	2
60	Modeling Contact Tracing Strategies for COVID-19 in the Context of Relaxed Physical Distancing Measures. <i>JAMA Network Open</i> , 2020, 3, e2019217.	2.8	38
61	Cost-effectiveness of post-treatment follow-up examinations and secondary prevention of tuberculosis in a high-incidence setting: a model-based analysis. <i>The Lancet Global Health</i> , 2020, 8, e1223-e1233.	2.9	15
62	Limitations of the UNAIDS 90-90-90 metrics: a simulation-based comparison of cross-sectional and longitudinal metrics for the HIV care continuum. <i>Aids</i> , 2020, 34, 1047-1055.	1.0	13
63	HCV Testing and Treatment in a National Sample of US Federally Qualified Health Centers during the Opioid Epidemic. <i>Journal of General Internal Medicine</i> , 2020, 35, 1477-1483.	1.3	12
64	Impact of Effective Global Tuberculosis Control on Health and Economic Outcomes in the United States. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1567-1575.	2.5	14
65	Adaptive guidelines for the treatment of gonorrhea to increase the effective life span of antibiotics among men who have sex with men in the United States: A mathematical modeling study. <i>PLoS Medicine</i> , 2020, 17, e1003077.	3.9	6
66	Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards Sustainable Development Goal 3. <i>Lancet</i> , 2020, 396, 693-724.	6.3	87
67	Evaluation of 6-Month Versus Continuous Isoniazid Preventive Therapy for Mycobacterium tuberculosis in Adults Living With HIV/AIDS in Malawi. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 643-650.	0.9	4
68	SUN-616 Poor Diagnostic Concordance Between Fasting Plasma Glucose and Glycosylated Hemoglobin in a Black South African Population. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.1	1
69	Exploring How Epidemic Context Influences Syphilis Screening Impact: A Mathematical Modeling Study. <i>Sexually Transmitted Diseases</i> , 2020, 47, 798-810.	0.8	6
70	Title is missing!. , 2020, 17, e1003077.		0
71	Title is missing!. , 2020, 17, e1003077.		0
72	Title is missing!. , 2020, 17, e1003077.		0

#	ARTICLE	IF	CITATIONS
73	Title is missing!. , 2020, 17, e1003077.		0
74	Depressive Symptoms and Their Relation to Age and Chronic Diseases Among Middle-Aged and Older Adults in Rural South Africa. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2019, 74, 957-963.	1.7	24
75	Is knowledge of HIV status associated with sexual behaviours? A fixed effects analysis of a female sex worker cohort in urban Uganda. <i>Journal of the International AIDS Society</i> , 2019, 22, e25336.	1.2	11
76	The impact of Medicare part D on income-related inequality in pharmaceutical expenditure. <i>International Journal for Equity in Health</i> , 2019, 18, 57.	1.5	2
77	Mapping 123 million neonatal, infant and child deaths between 2000 and 2017. <i>Nature</i> , 2019, 574, 353-358.	13.7	161
78	Measuring and correcting bias in indirect estimates of under-5 mortality in populations affected by HIV/AIDS: a simulation study. <i>BMC Public Health</i> , 2019, 19, 1516.	1.2	1
79	Multimorbidity and care for hypertension, diabetes and HIV among older adults in rural South Africa. <i>Bulletin of the World Health Organization</i> , 2019, 97, 10-23.	1.5	52
80	The Effect of HIV Self-Testing Delivery Models on Female Sex Workers'™ Sexual Behaviors: A Randomized Controlled Trial in Urban Uganda. <i>AIDS and Behavior</i> , 2019, 23, 1225-1239.	1.4	20
81	O14.1&...Optimizing screening for chlamydia: is there a role for screening heterosexual men?., 2019, , .		0
82	Chronic multimorbidity among older adults in rural South Africa. <i>BMJ Global Health</i> , 2019, 4, e001386.	2.0	66
83	Modelling hospital operations: insight from using data from paper registries in the obstetrics ward at a hospital in Addis Ababa, Ethiopia. <i>BMJ Global Health</i> , 2019, 4, e001281.	2.0	1
84	302. HCV Care in Federally Qualified Health Centers During the Opioid Epidemic: A Retrospective Cohort Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, S163-S163.	0.4	0
85	Does Incident Circumcision Lead to Risk Compensation? Evidence From a Population Cohort in KwaZulu-Natal, South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 269-275.	0.9	13
86	Integrating Economic Evaluation and Implementation Science to Advance the Global HIV Response. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, S314-S321.	0.9	3
87	Short-Term Effects and Long-Term Cost-Effectiveness of Universal Hepatitis C Testing in Prenatal Care. <i>Obstetrics and Gynecology</i> , 2019, 133, 289-300.	1.2	42
88	The Estimation and Projection Package Age-Sex Model and the r-hybrid model. <i>Aids</i> , 2019, 33, S235-S244.	1.0	30
89	Spatially targeted screening to reduce tuberculosis transmission in high-incidence settings. <i>Lancet Infectious Diseases</i> , The, 2019, 19, e89-e95.	4.6	41
90	The Impact of Screening and Partner Notification on Chlamydia Prevalence and Numbers of Infections Averted in the United States, 2000–2015: Evaluation of Epidemiologic Trends Using a Pair-Formation Transmission Model. <i>American Journal of Epidemiology</i> , 2019, 188, 545-554.	1.6	16

#	ARTICLE	IF	CITATIONS
91	The State of US Health, 1990-2016. JAMA - Journal of the American Medical Association, 2018, 319, 1444.	3.8	1,042
92	Progression from latent infection to active disease in dynamic tuberculosis transmission models: a systematic review of the validity of modelling assumptions. Lancet Infectious Diseases, The, 2018, 18, e228-e238.	4.6	79
93	The Burden of Cardiovascular Diseases Among US States, 1990-2016. JAMA Cardiology, 2018, 3, 375.	3.0	271
94	Tuberculosis control interventions targeted to previously treated people in a high-incidence setting: a modelling study. The Lancet Global Health, 2018, 6, e426-e435.	2.9	34
95	Population-level Outcomes and Cost-Effectiveness of Expanding the Recommendation for Age-based Hepatitis C Testing in the United States. Clinical Infectious Diseases, 2018, 67, 549-556.	2.9	53
96	Cohort Profile: Health and Ageing in Africa: A Longitudinal Study of an INDEPTH Community in South Africa (HAALSI). International Journal of Epidemiology, 2018, 47, 689-690j.	0.9	135
97	The Optimal Age for Screening Adolescents and Young Adults Without Identified Risk Factors for HIV. Journal of Adolescent Health, 2018, 62, 22-28.	1.2	23
98	Feasibility of a Healthâ€Utility Approach to Quantifying Noneconomic Losses from Personal Injury. Journal of Empirical Legal Studies, 2018, 15, 278-319.	0.5	0
99	Trading Bankruptcy for Health: A Discrete-Choice Experiment. Value in Health, 2018, 21, 95-104.	0.1	15
100	Inference With Difference-in-Differences With a Small Number of Groups. Medical Care, 2018, 56, 97-105.	1.1	33
101	The global burden of tuberculosis: results from the Global Burden of Disease Study 2015. Lancet Infectious Diseases, The, 2018, 18, 261-284.	4.6	246
102	Female Sex Workers Often Incorrectly Interpret HIV Self-Test Results in Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, e42-e45.	0.9	29
103	Predictors of male circumcision incidence in a traditionally non-circumcising South African population-based cohort. PLoS ONE, 2018, 13, e0209172.	1.1	9
104	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990â€2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1923-1994.	6.3	3,269
105	Population and fertility by age and sex for 195 countries and territories, 1950â€2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1995-2051.	6.3	294
106	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990â€2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1789-1858.	6.3	8,569
107	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 2091-2138.	6.3	335
108	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990â€2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1859-1922.	6.3	2,123

#	ARTICLE	IF	CITATIONS
109	Global, regional, and national burden of tuberculosis, 1990–2016: results from the Global Burden of Diseases, Injuries, and Risk Factors 2016 Study. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 1329-1349.	4.6	144
110	Global, Regional, and Country-Specific Lifetime Risks of Stroke, 1990 and 2016. <i>New England Journal of Medicine</i> , 2018, 379, 2429-2437.	13.9	959
111	Future Directions for Cost-effectiveness Analyses in Health and Medicine. <i>Medical Decision Making</i> , 2018, 38, 767-777.	1.2	58
112	The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Psychiatry</i> , the, 2018, 5, 987-1012.	3.7	885
113	Mortality due to low-quality health systems in the universal health coverage era: a systematic analysis of amenable deaths in 137 countries. <i>Lancet</i> , The, 2018, 392, 2203-2212.	6.3	528
114	High-quality health systems in the Sustainable Development Goals era: time for a revolution. <i>The Lancet Global Health</i> , 2018, 6, e1196-e1252.	2.9	1,721
115	Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 1191-1210.	4.6	1,084
116	Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 1211-1228.	4.6	862
117	The impact of measurement differences on cross-country depression prevalence estimates: A latent transition analysis. <i>PLoS ONE</i> , 2018, 13, e0198429.	1.1	11
118	Improving the Validity of Mathematical Models for HIV Elimination by Incorporating Empirical Estimates of Progression Through the HIV Treatment Cascade. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 596-604.	0.9	2
119	Disability weights for infectious diseases in four European countries: comparison between countries and across respondent characteristics. <i>European Journal of Public Health</i> , 2018, 28, 124-133.	0.1	10
120	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. <i>Lancet</i> , The, 2018, 391, 2236-2271.	6.3	638
121	Prospects for Tuberculosis Elimination in the United States: Results of a Transmission Dynamic Model. <i>American Journal of Epidemiology</i> , 2018, 187, 2011-2020.	1.6	58
122	Estimating the distribution of morbidity and mortality of childhood diarrhea, measles, and pneumonia by wealth group in low- and middle-income countries. <i>BMC Medicine</i> , 2018, 16, 102.	2.3	25
123	Evidence sources on the natural history of latent tuberculosis infection. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 834-835.	4.6	2
124	Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet</i> , The, 2018, 392, 1015-1035.	6.3	2,005
125	Measuring health and economic wellbeing in the Sustainable Development Goals era: development of a poverty-free life expectancy metric and estimates for 90 countries. <i>The Lancet Global Health</i> , 2018, 6, e843-e858.	2.9	18
126	Estimated Impact of Screening on Gonorrhea Epidemiology in the United States: Insights From a Mathematical Model. <i>Sexually Transmitted Diseases</i> , 2018, 45, 713-722.	0.8	9

#	ARTICLE	IF	CITATIONS
127	Treatment gaps and potential cardiovascular risk reduction from expanded statin use in the US and England. PLoS ONE, 2018, 13, e0190688.	1.1	15
128	Laboratory-based and office-based risk scores and charts to predict 10-year risk of cardiovascular disease in 182 countries: a pooled analysis of prospective cohorts and health surveys. Lancet Diabetes and Endocrinology, 2017, 5, 196-213.	5.5	90
129	The Use of Mathematical Models of Chlamydia Transmission to Address Public Health Policy Questions: A Systematic Review. Sexually Transmitted Diseases, 2017, 44, 278-283.	0.8	20
130	Hypertension management in a population of older adults in rural South Africa. Journal of Hypertension, 2017, 35, 1283-1289.	0.3	33
131	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015. JAMA Oncology, 2017, 3, 524.	3.4	4,254
132	Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. Journal of the American College of Cardiology, 2017, 70, 1-25.	1.2	2,705
133	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. Lancet, The, 2017, 390, 231-266.	6.3	480
134	Health Effects of Overweight and Obesity in 195 Countries over 25 Years. New England Journal of Medicine, 2017, 377, 13-27.	13.9	5,014
135	Child and Adolescent Health From 1990 to 2015. JAMA Pediatrics, 2017, 171, 573.	3.3	306
136	Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015. Lancet, The, 2017, 389, 1885-1906.	6.3	1,281
137	Screening Adolescents and Young Adults for HIV in the United States: A Cost-Effectiveness Analysis. Journal of Adolescent Health, 2017, 60, S18.	1.2	0
138	Improving Vignette Descriptions and Question Formats to Measure Distance Vision. Field Methods, 2017, 29, 175-193.	0.5	4
139	Impact of a Text-Messaging Program on Adolescent Reproductive Health: A Cluster–Randomized Trial in Ghana. American Journal of Public Health, 2017, 107, 298-305.	1.5	63
140	Catastrophic costs potentially averted by tuberculosis control in India and South Africa: a modelling study. The Lancet Global Health, 2017, 5, e1123-e1132.	2.9	41
141	The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level. JAMA Oncology, 2017, 3, 1683.	3.4	1,448
142	Cost-effectiveness of Testing and Treatment for Latent Tuberculosis Infection in Residents Born Outside the United States With and Without Medical Comorbidities in a Simulation Model. JAMA Internal Medicine, 2017, 177, 1755.	2.6	53
143	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1084-1150.	6.3	573
144	Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1260-1344.	6.3	1,589

#	ARTICLE	IF	CITATIONS
145	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1151-1210.	6.3	3,565
146	Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1211-1259.	6.3	5,578
147	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1345-1422.	6.3	1,879
148	Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1423-1459.	6.3	284
149	Population level outcomes and cost-effectiveness of expanding guidance for age-based hepatitis C testing in the United States. <i>Journal of Hepatology</i> , 2017, 66, S491.	1.8	0
150	Sexual Behaviors and HIV Status: A Population-Based Study Among Older Adults in Rural South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, e9-e17.	0.9	59
151	Disparities in Management of Cardiovascular Disease in Rural South Africa. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	0.9	9
152	Impact of Rapid Susceptibility Testing and Antibiotic Selection Strategy on the Emergence and Spread of Antibiotic Resistance in Gonorrhoea. <i>Journal of Infectious Diseases</i> , 2017, 216, 1141-1149.	1.9	62
153	Performance of self-reported HIV status in determining true HIV status among older adults in rural South Africa: a validation study. <i>Journal of the International AIDS Society</i> , 2017, 20, 21691.	1.2	33
154	Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofw266.	0.4	14
155	Awareness, treatment, and control of dyslipidemia in rural South Africa: The HAALSI (Health and Aging) Tj ETQq1 1 0.784314 rgBT /Over e0187347.	1.1	34
156	When cost-effective interventions are unaffordable: Integrating cost-effectiveness and budget impact in priority setting for global health programs. <i>PLoS Medicine</i> , 2017, 14, e1002397.	3.9	68
157	Prevalence and correlates of frailty in an older rural African population: findings from the HAALSI cohort study. <i>BMC Geriatrics</i> , 2017, 17, 293.	1.1	40
158	001.6–...Evaluating chlamydia trends in the united states 2000–2015 using a pair formation transmission model. , 2017, , .		0
159	Hepatitis C Testing Increased Among Baby Boomers Following The 2012 Change To CDC Testing Recommendations. <i>Health Affairs</i> , 2017, 36, 2142-2150.	2.5	34
160	The Effect of HIV and the Modifying Effect of Anti-Retroviral Therapy (ART) on Body Mass Index (BMI) and Blood Pressure Levels in Rural South Africa. <i>PLoS ONE</i> , 2016, 11, e0158264.	1.1	16
161	Sustainable Development in Surgery: The Health, Poverty, and Equity Impacts of Charitable Surgery in Uganda. <i>PLoS ONE</i> , 2016, 11, e0168867.	1.1	23
162	Costs of Routine Care for Chronic Hepatitis C Virus Infection: The Case of Illinois Medicaid. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0

#	ARTICLE	IF	CITATIONS
163	Comparative Effectiveness of Personalized Lifestyle Management Strategies for Cardiovascular Disease Risk Reduction. <i>Journal of the American Heart Association</i> , 2016, 5, e002737.	1.6	42
164	Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement. <i>Lancet, The</i> , 2016, 388, e19-e23.	6.3	687
165	Global, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1775-1812.	6.3	740
166	Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models. <i>The Lancet Global Health</i> , 2016, 4, e806-e815.	2.9	138
167	Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models. <i>The Lancet Global Health</i> , 2016, 4, e816-e826.	2.9	69
168	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1603-1658.	6.3	1,612
169	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1459-1544.	6.3	4,934
170	Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1545-1602.	6.3	5,298
171	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1659-1724.	6.3	4,203
172	Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1725-1774.	6.3	571
173	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1813-1850.	6.3	413
174	Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1093.	3.8	2,149
175	Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015. <i>Lancet HIV</i> , the, 2016, 3, e361-e387.	2.1	461
176	Diabetes diagnosis and care in sub-Saharan Africa: pooled analysis of individual data from 12 countries. <i>Lancet Diabetes and Endocrinology</i> , the, 2016, 4, 903-912.	5.5	108
177	Costs and cost-effectiveness of a mental health intervention for war-affected young persons: decision analysis based on a randomized controlled trial. <i>Health Policy and Planning</i> , 2016, 31, 415-424.	1.0	18
178	Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement. <i>PLoS Medicine</i> , 2016, 13, e1002056.	3.9	192
179	A latent transition analysis for the assessment of structured diagnostic interviews.. <i>Psychological Assessment</i> , 2015, 27, 975-984.	1.2	2
180	HIV burden in men who have sex with men: a prospective cohort study 2007–2012. <i>Scientific Reports</i> , 2015, 5, 11205.	1.6	30

#	ARTICLE	IF	CITATIONS
181	Evaluating the potential impact of enhancing HIV treatment and tuberculosis control programmes on the burden of tuberculosis. <i>Journal of the Royal Society Interface</i> , 2015, 12, 20150146.	1.5	9
182	Estimating distributions of health state severity for the global burden of disease study. <i>Population Health Metrics</i> , 2015, 13, 31.	1.3	59
183	Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2015, 386, 743-800.	6.3	4,951
184	The Global Burden of Cancer 2013. <i>JAMA Oncology</i> , 2015, 1, 505.	3.4	2,269
185	Using interviewer random effects to remove selection bias from HIV prevalence estimates. <i>BMC Medical Research Methodology</i> , 2015, 15, 8.	1.4	12
186	Disability weights for the Global Burden of Disease 2013 study. <i>The Lancet Global Health</i> , 2015, 3, e712-e723.	2.9	783
187	Assessing disability weights based on the responses of 30,660 people from four European countries. <i>Population Health Metrics</i> , 2015, 13, 10.	1.3	133
188	The Cost-Effectiveness of Sofosbuvir-Based Regimens for Treatment of Hepatitis C Virus Genotype 2 or 3 Infection. <i>Annals of Internal Medicine</i> , 2015, 162, 619-629.	2.0	92
189	A novel risk score to predict cardiovascular disease risk in national populations (GloboRisk): a pooled analysis of prospective cohorts and health examination surveys. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 339-355.	5.5	185
190	Stopping tuberculosis: a biosocial model for sustainable development. <i>Lancet, The</i> , 2015, 386, 2354-2362.	6.3	81
191	Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. <i>Lancet, The</i> , 2015, 386, 2145-2191.	6.3	1,544
192	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2015, 386, 2287-2323.	6.3	2,184
193	Estimating The Potential Impact Of Insurance Expansion On Undiagnosed And Uncontrolled Chronic Conditions. <i>Health Affairs</i> , 2015, 34, 1554-1562.	2.5	26
194	Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2015, 385, 117-171.	6.3	5,847
195	Effect of empirical treatment on outcomes of clinical trials of diagnostic assays for tuberculosis. <i>Lancet Infectious Diseases</i> , 2015, 15, 16-17.	4.6	12
196	Improving outcomes for caregivers through treatment of young people affected by war: a randomized controlled trial in Sierra Leone. <i>Bulletin of the World Health Organization</i> , 2015, 93, 834-841.	1.5	9
197	Teenage smoking behaviour following a high-school smoking ban in Chile: interrupted time-series analysis. <i>Bulletin of the World Health Organization</i> , 2015, 93, 468-475.	1.5	10
198	The Hepatitis C Cascade of Care: Identifying Priorities to Improve Clinical Outcomes. <i>PLoS ONE</i> , 2014, 9, e97317.	1.1	109

#	ARTICLE	IF	CITATIONS
199	Assessing and adjusting for differences between HIV prevalence estimates derived from national population-based surveys and antenatal care surveillance, with applications for Spectrum 2013. <i>Aids</i> , 2014, 28, S497-S505.	1.0	18
200	Who Needs Laboratories and Who Needs Statins?. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 25-32.	0.9	23
201	The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfecting patients. <i>Aids</i> , 2014, 28, 365-376.	1.0	20
202	Global, regional, and national levels of neonatal, infant, and under-5 mortality during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2014, 384, 957-979.	6.3	609
203	Population health impact and cost-effectiveness of monitoring inactive chronic hepatitis B and treating eligible patients in Shanghai, China. <i>Hepatology</i> , 2014, 60, 46-55.	3.6	41
204	Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2014, 384, 1005-1070.	6.3	786
205	Global, regional, and national levels and causes of maternal mortality during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2014, 384, 980-1004.	6.3	1,230
206	Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. <i>The Lancet Global Health</i> , 2014, 2, e23-e34.	2.9	188
207	The potential effects of changing HIV treatment policy on tuberculosis outcomes in South Africa. <i>Aids</i> , 2014, 28, S25-S34.	1.0	33
208	More Evidence on the Impact of India's Conditional Cash Transfer Program, Janani Suraksha Yojana: Quasi-Experimental Evaluation of the Effects on Childhood Immunization and Other Reproductive and Child Health Outcomes. <i>PLoS ONE</i> , 2014, 9, e109311.	1.1	59
209	The State of US Health, 1990-2010. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 591.	3.8	2,070
210	Disability weights for vision disorders in Global Burden of Disease study – Authors' reply. <i>Lancet, The</i> , 2013, 381, 23-24.	6.3	18
211	UK health performance: findings of the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2013, 381, 997-1020.	6.3	479
212	Life expectancy in Seychelles – Authors' reply. <i>Lancet, The</i> , 2013, 382, 23-24.	6.3	3
213	Incorporating Loss to Follow-up in Estimates of Survival Among HIV-Infected Individuals in Sub-Saharan Africa Enrolled in Antiretroviral Therapy Programs. <i>Journal of Infectious Diseases</i> , 2013, 207, 72-79.	1.9	18
214	Modelling national HIV/AIDS epidemics: revised approach in the UNAIDS Estimation and Projection Package 2011. <i>Sexually Transmitted Infections</i> , 2012, 88, i3-i10.	0.8	30
215	Spline-based modelling of trends in the force of HIV infection, with application to the UNAIDS Estimation and Projection Package. <i>Sexually Transmitted Infections</i> , 2012, 88, i52-i57.	0.8	21
216	HIV Treatment as Prevention: Systematic Comparison of Mathematical Models of the Potential Impact of Antiretroviral Therapy on HIV Incidence in South Africa. <i>PLoS Medicine</i> , 2012, 9, e1001245.	3.9	324

#	ARTICLE	IF	CITATIONS
217	Assessing the population health impact of market interventions to improve access to antiretroviral treatment. <i>Health Policy and Planning</i> , 2012, 27, 467-476.	1.0	4
218	National HIV prevalence estimates for sub-Saharan Africa: controlling selection bias with Heckman-type selection models. <i>Sexually Transmitted Infections</i> , 2012, 88, i17-i23.	0.8	33
219	HIV Treatment as Prevention: Issues in Economic Evaluation. <i>PLoS Medicine</i> , 2012, 9, e1001263.	3.9	37
220	Population Health Impact and Cost-Effectiveness of Tuberculosis Diagnosis with Xpert MTB/RIF: A Dynamic Simulation and Economic Evaluation. <i>PLoS Medicine</i> , 2012, 9, e1001347.	3.9	168
221	Disease burden and mental health system capacity: WHO Atlas study of 117 low- and middle-income countries. <i>British Journal of Psychiatry</i> , 2012, 201, 444-450.	1.7	23
222	GBD 2010: a multi-investigator collaboration for global comparative descriptive epidemiology. <i>Lancet, The</i> , 2012, 380, 2055-2058.	6.3	167
223	Healthy life expectancy for 187 countries, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2012, 380, 2144-2162.	6.3	804
224	GBD 2010: design, definitions, and metrics. <i>Lancet, The</i> , 2012, 380, 2063-2066.	6.3	868
225	Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2012, 380, 2129-2143.	6.3	1,013
226	Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2012, 380, 2197-2223.	6.3	7,061
227	Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2012, 380, 2095-2128.	6.3	11,038
228	Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2012, 380, 2163-2196.	6.3	6,376
229	A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2012, 380, 2224-2260.	6.3	9,397
230	Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis. <i>BMJ: British Medical Journal</i> , 2012, 344, e355-e355.	2.4	64
231	Effects of Healthcare Reforms on Coverage, Access, and Disparities. <i>American Journal of Preventive Medicine</i> , 2011, 41, 1-8.	1.6	80
232	Comparability of Patient-reported Health Status. <i>Medical Care</i> , 2011, 49, 962-970.	1.1	14
233	Non-monotonicity in the episodic random utility model. <i>Health Economics (United Kingdom)</i> , 2011, 20, 1523-1531.	0.8	3
234	Flexible epidemiological model for estimates and short-term projections in generalised HIV/AIDS epidemics. <i>Sexually Transmitted Infections</i> , 2010, 86, ii84-ii92.	0.8	22

#	ARTICLE	IF	CITATIONS
235	Preferences for health outcomes associated with Group A Streptococcal disease and vaccination. <i>Health and Quality of Life Outcomes</i> , 2010, 8, 28.	1.0	7
236	Event Rates, Hospital Utilization, and Costs Associated with Major Complications of Diabetes: A Multicountry Comparative Analysis. <i>PLoS Medicine</i> , 2010, 7, e1000236.	3.9	122
237	Clinical Benefits, Costs, and Cost-Effectiveness of Neonatal Intensive Care in Mexico. <i>PLoS Medicine</i> , 2010, 7, e1000379.	3.9	39
238	Modelling HIV epidemics in the antiretroviral era: the UNAIDS Estimation and Projection package 2009. <i>Sexually Transmitted Infections</i> , 2010, 86, ii3-ii10.	0.8	67
239	Exploring Model Uncertainty in Economic Evaluation of Health Interventions: The Example of Rotavirus Vaccination in Vietnam. <i>Medical Decision Making</i> , 2010, 30, E1-E28.	1.2	23
240	Causes of deaths in children younger than 5 years in China in 2008. <i>Lancet, The</i> , 2010, 375, 1083-1089.	6.3	186
241	Quantifying Child Mortality Reductions Related to Measles Vaccination. <i>PLoS ONE</i> , 2010, 5, e13842.	1.1	21
242	New disability weights for the global burden of disease. <i>Bulletin of the World Health Organization</i> , 2010, 88, 879-879.	1.5	49
243	THE FIRST AUTHOR REPLIES. <i>American Journal of Epidemiology</i> , 2009, 170, 1582-1583.	1.6	1
244	Are Americans Feeling Less Healthy? The Puzzle of Trends in Self-rated Health. <i>American Journal of Epidemiology</i> , 2009, 170, 343-351.	1.6	129
245	Tracking Population Health Based on Self-reported Impairments: Trends in the Prevalence of Hearing Loss in US Adults, 1976-2006. <i>American Journal of Epidemiology</i> , 2009, 170, 80-87.	1.6	25
246	Cost-effectiveness of Rotavirus vaccination in Vietnam. <i>BMC Public Health</i> , 2009, 9, 29.	1.2	47
247	Keep it simple: Ranking health states yields values similar to cardinal measurement approaches. <i>Journal of Clinical Epidemiology</i> , 2009, 62, 296-305.	2.4	43
248	Modeling Ranking, Time Trade-Off, and Visual Analog Scale Values for EQ-5D Health States. <i>Medical Care</i> , 2009, 47, 634-641.	1.1	63
249	Cost-Effectiveness of Cervical Cancer Screening With Human Papillomavirus DNA Testing and HPV-16,18 Vaccination. <i>Journal of the National Cancer Institute</i> , 2008, 100, 308-320.	3.0	199
250	Cost Effectiveness of Alternative Surveillance Strategies for Hepatocellular Carcinoma in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1418-1424.	2.4	225
251	Progress and challenges in modelling country-level HIV/AIDS epidemics: the UNAIDS Estimation and Projection Package 2007. <i>Sexually Transmitted Infections</i> , 2008, 84, i5-i10.	0.8	54
252	Evaluating the impact of antiretroviral therapy on HIV transmission. <i>Aids</i> , 2008, 22, S149-S159.	1.0	24

#	ARTICLE	IF	CITATIONS
253	Impact of HIV on novel therapies for tuberculosis control. <i>Aids</i> , 2008, 22, 963-972.	1.0	6
254	Economic evaluation of hepatitis B vaccination in low-income countries: using cost-effectiveness affordability curves. <i>Bulletin of the World Health Organization</i> , 2007, 85, 833-842.	1.5	49
255	Cost-effectiveness of HPV 16, 18 vaccination in Brazil. <i>Vaccine</i> , 2007, 25, 6257-6270.	1.7	139
256	Cost-effectiveness of Treatment for Hepatitis C in an Urban Cohort Co-infected with HIV. <i>American Journal of Medicine</i> , 2007, 120, 272-279.	0.6	22
257	Global Burden of Disease 2005: call for collaborators. <i>Lancet, The</i> , 2007, 370, 109-110.	6.3	114
258	Quantification of Health States with Rank-Based Nonmetric Multidimensional Scaling. <i>Medical Decision Making</i> , 2007, 27, 395-405.	1.2	23
259	Evolution of Antiretroviral Drug Costs in Brazil in the Context of Free and Universal Access to AIDS Treatment. <i>PLoS Medicine</i> , 2007, 4, e305.	3.9	95
260	Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. <i>Population Health Metrics</i> , 2007, 5, 11.	1.3	74
261	A Risk-Based Method for Modeling Traffic Fatalities. <i>Risk Analysis</i> , 2007, 27, 125-136.	1.5	57
262	Priority setting for health interventions in Mexico's System of Social Protection in Health. <i>Lancet, The</i> , 2006, 368, 1608-1618.	6.3	101
263	Cost-Effectiveness of Treating Multidrug-Resistant Tuberculosis. <i>PLoS Medicine</i> , 2006, 3, e241.	3.9	94
264	The burden of disease and injury in the United States 1996. <i>Population Health Metrics</i> , 2006, 4, 11.	1.3	170
265	Household and community socioeconomic and environmental determinants of child nutritional status in Cameroon. <i>BMC Public Health</i> , 2006, 6, 98.	1.2	137
266	Packaging Health Services When Resources Are Limited: The Example of a Cervical Cancer Screening Visit. <i>PLoS Medicine</i> , 2006, 3, e434.	3.9	26
267	Prospects for Advancing Tuberculosis Control Efforts through Novel Therapies. <i>PLoS Medicine</i> , 2006, 3, e273.	3.9	76
268	The Global Impact of Scaling Up HIV/AIDS Prevention Programs in Low- and Middle-Income Countries. <i>Science</i> , 2006, 311, 1474-1476.	6.0	116
269	Health impacts of macroeconomic crises and policies: determinants of variation in childhood malnutrition trends in Cameroon. <i>International Journal of Epidemiology</i> , 2006, 35, 648-656.	0.9	58
270	Integrating HIV Prevention and Treatment: From Slogans to Impact. <i>PLoS Medicine</i> , 2005, 2, e16.	3.9	117

#	ARTICLE	IF	CITATIONS
271	Enlightened Self-Interest and the Control of Tuberculosis. <i>New England Journal of Medicine</i> , 2005, 353, 1057-1059.	13.9	12
272	Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries. <i>BMJ: British Medical Journal</i> , 2005, 331, 1431-1437.	2.4	165
273	Estimating the Net Effect of HIV on Child Mortality in African Populations Affected by Generalized HIV Epidemics. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 38, 219-227.	0.9	71
274	Illness Transmission in the Home: A Possible Role for Alcohol-Based Hand Gels. <i>Pediatrics</i> , 2005, 115, 852-860.	1.0	62
275	Health-state valuations for pertussis: methods for valuing short-term health states. <i>Health and Quality of Life Outcomes</i> , 2005, 3, 17.	1.0	60
276	Taking account of future technology in cost effectiveness analysis. <i>BMJ: British Medical Journal</i> , 2004, 329, 733-736.	2.4	22
277	Enhancing the Validity and Cross-Cultural Comparability of Measurement in Survey Research. <i>American Political Science Review</i> , 2004, 98, 191-207.	2.6	736
278	Comparability of self rated health: cross sectional multi-country survey using anchoring vignettes. <i>BMJ: British Medical Journal</i> , 2004, 328, 258-0.	2.4	275
279	A multi-method approach to measuring health-state valuations. <i>Health Economics (United Kingdom)</i> , 2004, 13, 281-290.	0.8	64
280	Global patterns of healthy life expectancy in the year 2002. <i>BMC Public Health</i> , 2004, 4, 66.	1.2	76
281	Reconsidering the use of rankings in the valuation of health states: a model for estimating cardinal values from ordinal data. <i>Population Health Metrics</i> , 2003, 1, 12.	1.3	88
282	Healthy life expectancy: comparison of OECD countries in 2001. <i>Australian and New Zealand Journal of Public Health</i> , 2003, 27, 5-11.	0.8	35
283	Modified logit life table system: principles, empirical validation, and application. <i>Population Studies</i> , 2003, 57, 165-182.	1.1	120
284	Enhancing the Validity and Cross-Cultural Comparability of Measurement in Survey Research. <i>American Political Science Review</i> , 2003, 97, 567-583.	2.6	143
285	Cost-effectiveness of Treatment for Chronic Hepatitis C Infection in an Evolving Patient Population. <i>JAMA - Journal of the American Medical Association</i> , 2003, 290, 228.	3.8	214
286	Global Patterns of Healthy Life Expectancy for Older Women. <i>Journal of Women and Aging</i> , 2002, 14, 99-117.	0.5	22
287	Empirically Calibrated Model of Hepatitis C Virus Infection in the United States. <i>American Journal of Epidemiology</i> , 2002, 156, 761-773.	1.6	112
288	Can we reverse the HIV/AIDS pandemic with an expanded response?. <i>Lancet, The</i> , 2002, 360, 73-77.	6.3	143

#	ARTICLE	IF	CITATIONS
289	The Epidemiologic Transition Revisited: Compositional Models for Causes of Death by Age and Sex. Population and Development Review, 2002, 28, 205-228.	1.2	137
290	Healthy life expectancy in 191 countries, 1999. Lancet, The, 2001, 357, 1685-1691.	6.3	318
291	Feasibility of a Health Utilities Approach for Quantifying Noneconomic Losses from Personal Injury. SSRN Electronic Journal, 0, , .	0.4	0